CommercialPrior AuthMedium impact
Interleukin-1 Inhibitors (Arcalyst, Ilaris, Kineret)
Blue Cross & Blue Shield of Mississippi·MS · Rheumatology, Allergy & Immunology, Cardiology +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their prior authorization policy for three IL-1 inhibitor medications (Arcalyst, Ilaris, Kineret) used to treat rare inflammatory conditions. The policy establishes detailed medical necessity criteria including specific age requirements, genetic testing, and treatment history documentation for each medication and condition.
Action Required
Immediately: Billing team must update prior authorization workflows for Arcalyst (rilonacept), Ilaris (canakinumab), and Kineret (anakinra). Verify formulary coverage for each patient's specific benefit plan before prescribing. Providers must document detailed medical necessity criteria including genetic testing results, inflammatory markers, symptom history, and previous treatment failures as specified in policy L.5.01.485. Initial approvals are for 6 months, renewals for 12 months.